Relationship Covid-19 X Cannabidiol, a possible new coadjuvant in treatment?

Authors

DOI:

https://doi.org/10.33448/rsd-v10i3.13576

Keywords:

Covid-19; Cannabidiol; Cytokine Storm; Acute Respiratory Syndrome; Treatment.

Abstract

Among all Cannabinoids, Cannabidiol (CBD) proved to be significantly anti-inflammatory in a multiplicity of pathological conditions and with the lack of drugs and effective and 100% safe prophylaxis, inducing the scientific community to carry out several clinical trials, where they were done tests of the anti-inflammatory profile of the CBD associated with Lung Inflammation (Cytokine Storm) caused by the virus and similar conditions. Consequently, Covid-19 induces significant damage to humans through the storm of pro-inflammatory cytokines. A bibliographic search was made on Lung Inflammation related to viral inflammatory mediators and an alternative therapy, one found the use of Cannabidiol in clinical trials. It is important to note that Cannabidiol has several anti-inflammatory properties, which may represent a potential adjunctive therapeutic anti-inflammatory substance against inflammation induced by Covid-19 in defensive cells.

References

Adams, R., Hunt, M., & Clark, J. H. (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. Journal of the American chemical society, 62(1), 196-200

Arruza, L., Pazos, M. R., Mohammed, N., Escribano, N., Lafuente, H., Santos, M., & Martínez-Orgado, J. (2017). Cannabidiol reduces lung injury induced by hypoxic–ischemic brain damage in newborn piglets. Pediatric research, 82(1), 79-86.

Barbosa, M. G. A., Barros, É. F. A., de Lima, G. R., da Silva, G. F., & de Souza, P. G. V. D. (2020). O uso do composto de Canabidiol no tratamento da doença de Alzheimer (revisão da literatura). Research, Society and Development, 9(8), e442986073-e442986073.

Bergeret, J., & Leblanc, J. (1991). Toxicomanias: uma visão multidisciplinar. In Toxicomanias: uma visão multidisciplinar (pp. 354-354).

Bonfá, L., Vinagre, R. C. D. O., & Figueiredo, N. V. D. (2008). Uso de canabinóides na dor crônica e em cuidados paliativos. Revista Brasileira de Anestesiologia, 58(3), 267-279.

Cassol-Jr, O. J., Comim, C. M., Silva, B. R., Hermani, F. V., Constantino, L. S., Felisberto, F. & Dal-Pizzol, F. (2010). Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain research, 1348, 128-138.

Costiniuk, C. T., & Jenabian, M. A. (2020). Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?. Cytokine & growth factor reviews.

De Groot, R. J., Baker, S. C., Baric, R. S., Brown, C. S., Drosten, C., Enjuanes, L., & Ziebuhr, J. (2013). Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group. Journal of virology, 87(14), 7790-7792.

Dias, V. M. C. H., Carneiro, M., de Lacerda Vidal, C. F., Corradi, M. D. F. D. B., Brandão, D., da Cunha, C. A., ... & dos Santos Diego, L. A. (2020). Orientações sobre diagnóstico, tratamento e isolamento de pacientes com COVID-19. J Infect Control, 9(2), 56-75.

Duarte, C. (2012). O potencial analgésico dos canabinóides. Revista da Sociedade Portuguesa de Anestesiologia, 21(3), 13-18.

Esposito, G., Pesce, M., Seguella, L., Sanseverino, W., Lu, J., Corpetti, C., & Sarnelli, G. (2020). The potential of cannabidiol in the COVID‐19 pandemic. British journal of pharmacology, 177(21), 4967-4970.

Frutos-Vivar, F., Nin, N., & Esteban, A. (2004). Epidemiology of acute lung injury and acute respiratory distress syndrome. Current opinion in critical care, 10(1), 1-6.

Hussell, T., & Bell, T. J. (2014). Alveolar macrophages: plasticity in a tissue-specific context. Nature reviews immunology, 14(2), 81-93.

Khodadadi, H., Salles, É. L., Jarrahi, A., Chibane, F., Costigliola, V., Yu, J. C., ... & Baban, B. (2020). Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis and Cannabinoid Research, 5(3), 197-201.

Larsen, C., & Shahinas, J. (2020). Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. Journal of clinical medicine research,12(3), 129.

Matos, R. L., Spinola, L. A., Barboza, L. L., Garcia, D. R., França, T. C., & Affonso, R. S. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual de Química, 9(2), 786-814.

Mechoulam, R., & Shvo, Y. (1963). Hashish—I: the structure of cannabidiol. Tetrahedron, 19(12), 2073-2078.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.[e-book]. Santa Maria. Ed (pp. 3-9). UAB/NTE/UFSM. Disponível em: https://repositorio. ufsm. br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica. Pdf.

Perlman, S. (2020). Another decade, another coronavirus.

Pernoncini, K. V., & Oliveira, R. M. M. W. (2014). Usos terapêuticos potenciais do canabidiol obtido da Cannabis sativa. Revista Uningá Review, 20(3).

Pimentel, B. N. (2020). As disfunções olfativas e gustativas como apresentação clínica da COVID-19. Research, Society and Development, 9(8), e64985072. https://doi.org/10.33448/rsd-v9i8.5072

Rizzo, M. D., Crawford, R. B., Henriquez, J. E., Aldhamen, Y. A., Gulick, P., Amalfitano, A., & Kaminski, N. E. (2018). HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-γ-inducible protein 10 levels compared with nonusing HIV patients. Aids, 32(4), 419-429.

Saguil, A., & Fargo, M. V. (2020). Acute Respiratory Distress Syndrome: Diagnosis and Management. American family physician, 101(12), 730–738.

Salles, É. L., Khodadadi, H., Jarrahi, A., Ahluwalia, M., Paffaro Jr, V. A., Costigliola, V., ... & Baban, B. (2020). Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. Journal of Cellular and Molecular Medicine, 24(21), 12869-12872.

Sousa, G. O., Sales, B. N., Rodrigues, A. M. X., Rocha, G. M. de M., & Oliveira, G. A. L. de. (2020). Evolução epidemiológica da COVID-19 no Brasil e no mundo. Research, Society and Development, 9(7), e630974653. https://doi.org/10.33448/rsd-v9i7.4653

Sørensen, M. D., Sørensen, B., GONZALEZ‐DOSAL, R. E. G. I. N. A., Melchjorsen, C. J., Weibel, J., Wang, J., ... & Kristensen, P. (2006). Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals. Annals of the New York Academy of Sciences, 1067(1), 500.

Vuolo, F., Abreu, S. C., Michels, M., Xisto, D. G., Blanco, N. G., Hallak, J. E., ... & Dal-Pizzol, F. (2019). Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European journal of pharmacology, 843, 251-259.

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., ... & Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270-273.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., ... & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine.

Published

23/03/2021

How to Cite

ARAÚJO, R. K. S. . Relationship Covid-19 X Cannabidiol, a possible new coadjuvant in treatment?. Research, Society and Development, [S. l.], v. 10, n. 3, p. e48710313576, 2021. DOI: 10.33448/rsd-v10i3.13576. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/13576. Acesso em: 8 may. 2021.

Issue

Section

Review Article